Ammonia N 13 - 2007 FDA approvals

Getting the most out of First-in-Human and Early Clinical Trials
In a follow-up to our webinar last month on first-in-human drug studies, FierceBiotech edi
Active Directory & the Cloud for Biotech & Pharma
Biotech and pharmaceutical companies are leaders cloud/SaaS technology adoption. This webi
Prepare Your Compliance Systems and Processes for the Physician Payments Sunshine Act
Beginning in 2012, pharmaceutical, biotechnology and medical device companies will be requ
Drug Development: An Overview of the Regulated Clinical Trials Process Used to Bring a New Drug to Market
Join us for a one-hour overview of the regulated clinical trials process used to bring a n

January 9, 2008 — 2:10pm ET | By Maureen Martino

Tools

Drug: Ammonia N 13
Indication: PET scanning
Company: Feinstein
Approval Date: August 27, 2007

Scoop: Feinstein's Ammonia N 13 is a radiopharmaceuticals that allows physicians to get a clearer look inside the human body during PET scans. The approval is for PET imaging of the myocardium to diagnose suspected or existing coronary heart disease.

SHARE
WITH:

Most Popular Stories

Webinars

Featured Jobs

Events

Ammonia N 13 - 2007 FDA approvals

THE FIERCEMARKETS NETWORK